Evaluation of serum adipocytokine and interleukin-18 levels in patients with epilepsy

Abstract

Objective: Epilepsy is a neurological disease characterized by recurrent seizures. The underlying pathophysiological mechanisms in epilepsy are not fully known. Our aim is to investigate the relationship between serum adipocytokine and interleukin (IL)-18 levels in epilepsy patients receiving and not receiving antiepileptic therapy. Method: Our study was established as three groups. I: Epilepsy patients receiving antiepileptic therapy (n=30), II: Newly diagnosed epilepsy patients (n=30) and III: Control group (n=30). Serum adipocytokine and IL-18 levels were measured by enzyme-linked immunoassorbent assay method. Results: It was determined that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received topiramate treatment and did not receive antiepileptic therapy compared to the control group. Serum glucose, total protein, cholesterol and albumin concentrations of patients who received antiepileptic treatment were decreased compared to the control group (p<0.001). It was found that serum adipocytokine and IL-18 concentration in epilepsy patients who received topiramate treatment decreased compared to patients who did not receive treatment, but it was not significant (p>0.05). It was found that the body mass index (BMI) ratio of epilepsy patients who received antiepileptic treatment decreased and was significant compared to the control group and the group that did not receive treatment (p<0.01). Conclusion: In our study, it was shown that serum adipocytokine and IL-18 levels were increased in epilepsy patients who received and did not receive antiepileptic therapy. Findings from this study suggest that adipocytokine and IL-18 may be useful markers for the inflammatory process of epileptogenesis.

Keywords

• Topiramate
• Interleukin-18
• Adipocytokine
• Epilepsy

References

1. Hamed SA. The vascular risk associations with migraine: relation to migraine susceptibility and progression. Atherosclerosis 2009;205(1):15-22. https://doi.org/10.1016/j.atherosclerosis.2008.10.016
2. Sachdev A, Marmura MJ. Metabolic syndrome and migraine. Front Neurol 2012 19;3:161. https://doi.org/10.3389/fneur.2012.00161
3. Klein P, Dingledine R, Aronica E, Bernard C, Blümcke I, Boison D, et al. Commonalities in epileptogenic processes from different acute brain insults: Do they translate?Epilepsia 2018;59(1):37-66. https://doi.org/10.1111/epi.13965
4. Liebner S, Dijkhuizen RM, Reiss Y, Plate KH, Agalliu D, Constantin G. Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol 2018;135(3):311-336. https://doi.org/10.1007/s00401-018-1815-1
5. Maroso M, Balosso S, Ravizza T, Liu J, Aronica E, Iyer AM, et al. Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat Med 2010;16(4):413-9. https://doi.org/10.1038/nm.2127
6. Klöting N, Berndt J, Kralisch S, Kovacs P, Fasshauer M, Schön MR, et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes. Biochem Biophys Res Commun 2006;339(1):430-6. https://doi.org/10.1016/j.bbrc.2005.11.039
7. Wada J Vaspin. A novel serpin with insulin-sensitizing effects.Expert Opin Investig Drugs 2008;17(3):327-33. https://doi.org/10.1517/13543784.17.3.327
8. Luk T, Malam Z, Marshall JC.Pre-B cell colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate immunity.J Leukoc Biol 2008;83(4):804-16. https://doi.org/10.1189/jlb.0807581

9. Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H, et al. H.Visfatin, an adipocytokine with proinflammatory and immunomodulating properties.J Immunol 2007;178(3):1748-58. https://doi.org/10.4049/jimmunol.178.3.1748
10. Zabel BA, Allen SJ, Kulig P, Allen JA, Cichy J, Handel TM, et al. EC.Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 2005;280(41):34661-6. https://doi.org/10.1074/jbc.M504868200
11. Takahashi M, Takahashi Y, Takahashi K, Zolotaryov FN, Hong KS, Kitazawa R,et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes. FEBS Lett 2008;582(5):573-8. https://doi.org/10.1016/j.febslet.2008.01.023
12. Leslie JA, Meldrum KK. The role of interleukin-18 in renal injury. J Surg Res 2008;145(1):170-5. https://doi.org/10.1016/j.jss.2007.03.037
13. Meral C, Cekmez F, Vurucu S, Tascılar E, Pirgon O, Canpolat FE, et al. New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid. Eur Cytokine Netw 2011;22(2):118-22.: https://doi.org/10.1684/ecn.2011.0284
14. Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.Epilepsia 2017;58(4):522-530. https://doi.org/10.1111/epi.13670
15. Si J, Wang S, Liu N, Yang X, Wang Y, Li L, et al. Anticonvulsant effect of exogenous β-hydroxybutyrate on kainic acid-induced epilepsy. Exp Ther Med. 2017 Jul;14(1):765-770. https://doi.org/10.3892/etm.2017.4552
16. Scorza CA, Marques MJG, Gomes da Silva S, Naffah-Mazzacoratti MDG, Scorza FA, Cavalheiro EA. Status epilepticus does not induce acute brain inflammatory response in the Amazon rodent Proechimys, an animal model resistant to epileptogenesis..Neurosci Lett. 2018 Mar 6;668:169-173. doi: 10.1016/j.neulet.2017.02.049. Epub 2017 Feb 22. https://doi.org/10.1016/j.neulet.2017.02.049
17. Alboni S, Cervia D, Sugama S, Conti B. Interleukin 18 in the CNS. JNeuroinflammation 2010;7:9. https://doi.org/10.1186/1742-2094-7-9
18. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, et al. Cloningof a new cytokine that induces IFN-gamma production by T cells. Nature1995;378:88–91. https://doi.org/10.1038/378088a0
19. Dinarello CA. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999;103:11–24.). https://doi.org/10.1016/S0091-6749(99)70518-X
20. Liu R, Wu S, Guo C, Hu Z, Peng J, Guo K, et al. Li Ibuprofen Exerts Antiepileptic and Neuroprotective Effects in the Rat Model of Pentylenetetrazol-Induced Epilepsy via the COX-2/NLRP3/IL-18 Pathway.
21. J.Neurochem Res. 2020 Oct;45(10):2516-2526. doi: 10.1007/s11064-020-03109-9. Epub 2020 Aug 13. https://doi.org/10.1007/s11064-020-03109-9
22. Mochol M, Taubøll E, Sveberg L, Tennøe B, Berg Olsen K, Heuser K, et al. Seizure control after late introduction of anakinra in a patient with adult onset Rasmussen’s encephalitis.Epilepsy Behav Rep 2021;16:100462. https://doi.org/10.1016/j.ebr.2021.100462 Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesityand insulin resistance. Arterioscler Thromb Vasc Biol 2005;25:1268–73. https://doi.org/10.1161/01.ATV.0000163843.70369.12
23. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes.Clin Endocrinol (Oxf) 2010;72(3):342-8. https://doi.org/10.1111/j.1365-2265.2009.03664.x
24. Rourke JL, Dranse HJ, Sinal CJ. Towards an integrative approach to understanding the role of chemerin in human health and disease.Obes Rev 2013;14(3):245-62. https://doi.org/10.1111/obr.12009
25. Elhady M, Youness ER, Gafar HS, Abdel Aziz A, Mostafa RSI. Circulating irisin and chemerin levels as predictors of seizure control in children with idiopathic epilepsy.Neurol Sci. 2018;39(8):1453-1458. https://doi.org/10.1007/s10072-018-3448-5
26. Adya R, Tan BK, Chen J, Randeva HS.Nuclear factor-kappaB induction by visfatin in human vascular endothelial cells: its role in MMP-2/9 production and activation.Diabetes Care 2008;31(4):758-60. https://doi.org/10.2337/dc07-1544
27. Lee WJ, Wu CS, Lin H, Lee IT, Wu CM, Tseng JJ, et al. Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway. I nt J Obes (Lond) 2009;33(4):465-72. https://doi.org/10.1038/ijo.2009.24
28. Meral C, Cekmez F, Vurucu S, Tascılar E, Pirgon O, Canpolat FE, et al. New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid.Eur Cytokine Netw 2011;22(2):118-22. https://doi.org/10.1684/ecn.2011.0284
29. Sonmez FM, Zaman D, Aksoy A, Deger O, Aliyazicioglu R, Karaguzel G, et al. The effects of topiramate and valproate therapy on insulin, c-peptide, leptin, neuropeptide Y, adiponectin, visfatin, and resistin levels in children with epilepsy. Seizure 2013;22(10):856-61. https://doi.org/10.1016/j.seizure.2013.07.007
30. Hida K, Wada J, Eguchi J, Zhang H, Baba M, Seida A, et al. Visceral adipose tissue-derived serine protease inhibitor: a unique insulin-sensitizing adipocytokine in obesity. Proc Natl Acad Sci U S A 2005;102(30):10610-5. https://doi.org/10.1073/pnas.0504703102
31. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16(10):961-6. https://doi.org/10.1016/S0899-9007(00)00452-4
32. Li HF, Zou Y, Xia ZZ, Gao F, Feng JH, Yang CW. Effects of topiramate on weight and metabolism in children with epilepsy.Acta Paediatr 2009;98:1521-5.). https://doi.org/10.1111/j.1651-2227.2009.01349.x
33. Uludağ Fİ, Şener U, Zorlu Y, Köseoğlu MH, Kantaroğlu Aydın T. Serum Leptin Levels in Epileptic Patients Treated with Topiramate and Valproic Acid. Turk J Neurol. 2011; 17(1): 17-3.
34. Lalonde J, Samson P, Poulin S, Deshaies Y, Richard D Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice. Physiol Behav 2004;80(4):415-20. https://doi.org/10.1016/j.physbeh.2003.08.013
35. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats. Obes Res 2000;8:656-63. https://doi.org/10.1038/oby.2000.84
36. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11(4):556-62. https://doi.org/10.1038/oby.2003.78